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Mechanisms in the development of analgesic nephropathy
GEOFFREY G. DUGGIN
Renal Unit, Royal Prince Alfred Hospital, Camperdown, Sydney, Australia
Analgesic nephropathy is a unique drug-induced
kidney disease. It is characterized by renal papillary
necrosis and interstitial nephritis resulting from pro-
longed excessive consumption of combination anti-
pyretic analgesics.
Antipyretic analgesics have been used in clinical
medicine since the late nineteenth century. Buss in-
troduced sodium salicylate in 1895, Dresser in-
troduced aspirin in 1897, phenacetin in 1887, and
Von Merring introduced paracetamol (acetamino-
phen) in 1893 [1]. These drugs have found wide-
spread use as everyday remedies in almost every
country in the world. It was not until 1953, how-
ever, that Spuehier and Zollinger [2] described the
renal disease associated with the chronic consump-
tion of combination analgesics containing phenace-
tin.
There is now overwhelming evidence that con-
sumption of combination analgesics is causally as-
sociated with renal disease. Clinical and epidemio-
logic studies indicate an increased incidence of re-
nal disease in people who abuse analgesics.
Nordenfelt and Ringertz [3] found that 29% of
people who had consumed an estimated kilogram
or greater of phenacetin in a combination analgesic
had evidence of renal damage. Larsen and Moller
[4] found that 33% of people with a similar intake
had reduced renal function, as evidenced by a de-
crease in creatinine clearance, compared with only
7% in a matched control group. Others have report-
ed the incidence of renal impairment to vary be-
tween 3 and 90%, being greater in each instance
than in the normal population with which they were
compared. The apparent discrepancies result from
the different methods used to determine renal func-
tion, the amount of drugs consumed, and the dif-
ferent combinations of analgesics. The incidence of
analgesic abuse in patients with renal disease fur-
ther supports a causal relationship. Murray and
Goldberg [5] reported that 20% of patients with
chronic interstitial nephritis abused analgesics.
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Olfsson, Gudmundsson, and Brekkan [6] studied 49
unselected patients with nonobstructive pyelone-
phritis without diabetes mellitus or stones and found
38% abused analgesics. Data from the Australian
and New Zealand Dialysis and Transplant Registry
[7] also showed that patients who abused combina-
tion analgesics developed renal disease, and ap-
proximately 20% of patients on the Australian pro-
gram for dialysis and transplant were there as a re-
sult of analgesic-induced kidney disease. The
correlation between the severity of renal disease
and the extent of analgesic abuse had been demon-
strated by Gault, Blennerhassett, and Muehrcke
[8], who found a linearly increased relationship be-
tween the amount of analgesic consumed and the
severity of renal disease, as assessed by creatinine
clearance and renal biopsy. Nordenfelt [9] also
showed that the decreased availability of phenace-
tin-containing compound analgesics in Sweden had
led to a marked decline in the incidence of kidney
disease in that country. The incidence of patients
with analgesic nephropathy per country also re-
markably parallels the per capita consumption of
phenacetin in that country [5]. In 1967, Australia
had a per capita consumption of phenacetin of 40 g
per year, and the highest incidence of analgesic ne-
phropathy. This was followed by Scandinavia with
25 g; Switzerland with 22 g and South Africa and
Scotland with 12 g per year. In Canada and the
USA, the disease is relatively uncommon, and the
per capita consumption was 7 g and 10 g, respec-
tively. Further evidence implicating analgesics was
provided by two studies that examined the cessa-
tion of analgesic consumption by patients who had
abused them. Linton [10] showed that patients who
ceased analgesic consumption either maintained or
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improved renal function, whereas those who con-
tinued to consume analgesics had a further deterio-
ration. A similar study in Australia [11] showed
comparable results.
Until 1964, it was widely accepted that phenace-
tin was the agent primarily responsible for the dis-
ease. This was largely based on clinical data from
Western Europe, particularly Switzerland and Swe-
den. Gilman, in an editorial [12], questioned the va-
lidity of the theory that phenacetin caused the dis-
ease. This resulted in considerable controversy as
to which drug was responsible for the disease. Nan-
ra et al [13] found that aspirin in doses of 500 mg/kg/
day or phenacetin or paracetamol in doses of 3000
mg/kg/day resulted in a disease in rats similar to the
analgesic-induced disease in man. They suggested
that aspirin was more likely to be the principal
agent. The doses used in their animals, however,
bore no relationship to those consumed by man, as
they exceeded the expected lethal dose. Also, as
several drugs produce the disease, species dif-
ferences in drug metabolism and pharmacokinetics
may change the dose relationship in man [14]. Nan-
ra and Kincaid Smith [15] also provided further evi-
dence from a pathology study of patients who had
rheumatoid arthritis, treated with high dose salicy-
lates. it was found that 59% of autopsy specimens
had evidence of papillary necrosis. But this study
was retrospective, and no data are available regard-
ing the abuse of combination analgesics—important
in this group of patients who, in Australia, are
known to use nonmedically prescribed combination
analgesics in addition to their medically prescribed
medications [16].
Several studies question the primary role of aspi-
rin. Leonards [17] was unable to produce analgesic
nephropathy in 200 rats treated with 500 mg/kg/day
of aspirin over a 6-month period. Phillips et al [18]
used doses more closely approaching those of hu-
man consumption (24 to 126 mg/kg/day) and found
no evidence that aspirin alone could induce renal
disease. Studies of pigs [19] given aspirin for 6
months produced no evidence of papillary necrosis.
Several clinical studies also refuted the role of aspi-
rin as a sole drug. The New Zealand Rheumatism
Association study [20] of 1081 patients with rheu-
matic diseases treated with salicylates showed that
the only patients with evidence of renal disease
were a small group who had abused aspirinlphe-
nacetin or aspirinlparacetamol combinations. This
was also supported by a prospective study in New-
castle-on-Tyne [21] of patients with rheumatic dis-
ease who were treated over a 2-year period with
high dose salicylates and who had no change in re-
nal function.
Until recently, most investigators have concen-
trated on a single drug being responsible for the dis-
ease. As there is a striking association between the
abuse of combination analgesics and the disease,
this raises the possibility of synergistic toxicity with
the combination of these drugs [14]. Clinical evi-
dence to support this contention is provided by Fer-
guson et al. [16], who studied patients attending a
clinic for rheumatism. Patients who had consumed
in excess of 1 kg of aspirin alone had a 0.3% in-
cidence of papillary necrosis, whereas patients who
had consumed in excess of 1 kg of combination an-
algesics containing aspirin and phenacetin or para-
cetamol had a 10.6% incidence of the disease. A
prospective study by Dubach et a! [22] in Switzer-
land provided evidence that combination analgesics
containing phenacetin produced evidence of renal
disease. The study involved 623 people employed in
watch factories in Switzerland. These subjects were
found to have phenacetin metabolites (measured as
paracetamol) present in their urine, and were com-
pared to an age-, sex-, and occupation-matched
control group, who had no drug present. Over the 4-
year period of study, 3.8% of the phenacetin group
developed an abnormal urine concentrating capac-
ity, against 0.8% of the control group. The in-
cidence of raised serum creatinine was 2.9% in the
phenacetin group and 0.4% in the control group.
The data were even more significant when the phe-
nacetin group was subdivided into those showing
evidence of high and low consumption: 5.4% of the
high consumption group and 0.4% of the low con-
sumption group had raised serum creatinine levels.
These relatively small percentages are more impor-
tant when one considers that plasma creatinine does
not become elevated above the normal range until
almost 50% of renal function is lost; also, that in
papillary necrosis, extensive disease with consid-
erable scarring is present before any significant
change occurs in creatinine clearance [23].
Recently, the pathology of the disease has been
reviewed extensively [24, 25]. Lindeneg et a! [26]
suggested that the disease commenced in the renal
papillae and resulted in necrosis of this anatomical-
ly discrete tissue. This then may lead to secondary
nephron damage. Gault, Blennerhassett, and
Muehrcke [8], in a study of patients with analgesic
nephropathy, using percutaneous renal biopsy, con-
firmed and extended these findings; the initial lesion
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is necrosis, particularly of interstitial cells, and
some sclerosis of the renal papillae. As the quantity
of analgesic consumed increases, there is complete
necrosis of the renal medulla; this is then followed
by nephron death and cortical interstitial nephritis,
often associated with separation of the renal pa-
pillae or portions thereof.
In Australia, it has been demonstrated that the
presentation of patients to a hospital is more com-
mon in summer than it is winter and that the disease
has acute exacerbations during episodes of dehy-
dration [27]. One of the major contributing factors
to this phenomenon is the high concentration of the
drug in the papilla during these episodes, leading to
selective tissue damage.
Hypotheses for pathophysiologic mechanism
For a drug to induce selective damage to the renal
papillae, the drug or its derivative must satisfy one
or both of the following criteria: (1) The tissue must
have unique metabolic or functional features that
render it sensitive to the drug. (2) The drug must be
concentrated selectively within that tissue.
With regard to the first hypothesis, several work-
ers have suggested that the principal event is is-
chemic necrosis of the papillae, because of the na-
ture of the blood supply to this tissue. Molland [28]
demonstrated changes within the vasa recta epithe-
hum and postulated a decreased papillary blood
flow leading to ischemic necrosis. Nanra, Chira-
wong, and Kincaid Smith [29] have demonstrated in
rats given 500 mg/kg of aspirin a decreased medul-
lary blood volume, as determined by the fluorescent
tanned red cell method. Their data do not, however,
show decreased blood flow to the papilla, as the
method used determines blood volume and not
blood flow, and the tissue swelling associated with
papillary necrosis may alone be sufficient to ac-
count for the decreased blood volume within the tis-
sue. They have postulated that there may be inhibi-
tion of renomedullary prostaglandins. Caterson and
Duggin [30] demonstrated that small doses of aspi-
rin noncompetitively inhibit prostaglandin synthe-
tase in the kidney, both in the renal cortex and the
renal medulla. If this were the mechanism, people
consuming small doses of aspirin daily might be ex-
pected to develop the disease, but this has not been
demonstrated.
With respect to the second hypothesis—that the
drug becomes concentrated within the tissue as a
result of the renal excretory mechanism, and under-
goes metabolism to produce tissue necrosis—a
great deal of data have been accumulated.
Renal excretory mechanisms of analgesics
Phenacetin. Metabolic studies indicate that this
compound undergoes extensive first-pass metabo-
lism in the liver to paracetamol, so that only when
large doses are consumed do even small concentra-
tions appear in the peripheral circulation [31]. Phe-
nacetin is only weakly protein bound to plasma pro-
teins [32], undergoes glomerular filtration, and is
passively reabsorbed by the tubule [32]. The drug is
very lipid soluble, and at all urine flow rates the
urine-to-plasma ratio (U/P ratio) remains in unity.
This indicates a diffusion rate from the tubular lu-
men equal to that of water. The phenacetinlinulin
clearance ratio rises linearly with the urine flow
rate. The plasma concentration of phenacetin and
the urine pH have no influence on the clearance of
phenacetin by the kidney. A stop-flow study [32] in-
dicated no specific site of reabsorption of phenace-
tin along the tubule, the urine-to-plasma ratio in
both proximal and distal regions being in unity.
Paracetamol (acetaminophen). Barraclough [33]
showed that the U/P ratio of paracetamol increased
in response to vasopressin. Prescott and Wright [34]
demonstrated in man that paracetamol clearance
was increased by increased urine flow rate and not
influenced by urine pH. They also showed that ex-
cretion of the major conjugates of paracetamol was
not affected by urine flow. Duggin and Mudge [35]
examined the mechanisms of tubular transport in
dogs, and found close agreement with the findings
of Prescott and Wright. In the dog, paracetamol is
only approximately 13% protein bound, and hence
undergoes glomerular filtration. Clearance increas-
es with an increase in urine flow rate in a curvilinear
manner, somewhat similar to urea. The fractional
excretion of paracetamol is 0.26 when the fractional
excretion of water is 0.05; this increases to 0.40
when the fractional excretion of water rises to 0.12.
The clearance is independent of the plasma concen-
tration of the drug, and urine pH has no effect. Sil-
berbush et a! [36] studied paracetamol clearance
during paracetamol loading and following loading.
They also found renal accumulation of paracetamol.
Their clearance data are in close agreement with
those of Duggin and Mudge, as are also the findings
of Ross et al [37], who studied the renal clearance of
paracetamol in the isolated perfused rat kidney.
The conjugates of paracetamol have quite dif-
ferent mechanisms of transport. At low plasma con-
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centrations, both the sulphate and glucuronide con-
jugates undergo net tubular secretion. At high plas-
ma concentrations, net tubular secretion decreases
and net tubular reabsorption becomes apparent.
Tubular secretion at low plasma concentrations is
inhibited by probenecid. These data suggest that the
conjugates of paracetamol undergo bidirectional ac-
tive transport within the proximal tubule. Stop-flow
studies [35] demonstrated that for paracetamol
there was no specific site of reabsorption and the
rate of diffusion was less than that of water. The
conjugates of paracetamol had a proximal site of
reabsorption, and this was inhibited by probenecid.
Aspirin. Although the renal excretory mecha-
nisms of salicylate have been investigated exten-
sively since the 1940's, (see below), those of aspirin
have not. The reason has been the lability of aspirin
in biologic fluids [30]. Recent methods of analysis,
especially high-pressure liquid chromatography
[39], have overcome many of these problems. Stud-
ies in the rabbit (Caterson and Duggin, unpublished)
are complicated by the rapid in vivo conversion of
aspirin to salicylate. This introduces at least three
problems in the measurement and interpretation of
renal clearance: First, the tubular transport of aspi-
rin must always be measured in the presence of var-
iable concentrations of another organic anion, for
example, salicylate, which acts as a competitor for
active transport. Second, the extent of the revers-
ible binding of aspirin to plasma protein can only be
measured with an error of unknown degree, be-
cause aspirin undergoes a rapid transacetylation re-
action with protein which yields acetylated protein
and salicylate as products [30, 40]. It is not known
whether the binding of aspirin is the same for ace-
tylated as for nonacetylated proteins. Third, aspirin
acetylates kidney protein directly. Except at very
low doses, this process is dose-dependent and is un-
saturatable at high single doses of aspirin [30]. It is
not known to what extent reactions of this type dis-
tort the usual estimates of tubular transport that are
made in the conventional manner on the basis of
clearance data.
Despite the above limitations, aspirin appears to
behave in a manner qualitatively similar to that of
salicylate. At low plasma concentrations, there is
net tubular secretion that is probenecid-sensitive; at
high plasma concentrations, there is net tubular
reabsorption. These data suggest bidirectional ac-
tive transport in the proximal tubule. In addition,
aspirin excretion is increased by alkalinization of
the urine or an increase in the rate of urine flow.
These findings suggest that reabsorptive transport
also occurs by nonionic diffusion.
Saucy/ate. Studies in several species, including
man, identify at least three components in the renal
disposition of salicylate: filtration (of that fraction
that is not bound to plasma protein), active secre-
tory transport in the proximal tubule, and nonionic
diffusive reabsorption throughout most of the neph-
ron [38, 41, 42]. It has been suggested that in addi-
tion to nonionic diffusion, a specifically mediated
reabsorptive mechanism for salicylate exists in the
proximal tubule [42]. The importance of nonionic
diffusion as a determinant of salicylate excretion is
indicated by the fact that clearance may range from
virtually zero at low urinary pH to values exceeding
the filtration rate at high urinary pH. As expected,
clearance is positively correlated with urine flow
rate. Under stable physiologic conditions, clear-
ance diminishes as plasma concentration of salicy-
late increases. This phenomenon is thought to be a
consequence of saturating the secretory mechanism
[41].
Intrarenal distribution of analgesics
A limited number of drugs have been studied with
respect to their distribution in the kidney. Most re-
ports have been confined to the concentration with-
in the total tissue, and most authors have not deter-
mined any compartmental distribution within the
kidney. This is particularly important in the kidney,
as this organ has an intratubular compartment in ad-
dition to the usual intracellular and interstitial com-
partments. Hence, it is possible for two compounds
to have equal total tissue concentrations, one com-
pound being distributed evenly throughout all com-
partments and the second being concentrated only
within a singular compartment. This is particularly
important when considering drug toxicity, because
it is probable that the mechanism of toxicity in-
volves an intracellular site of action. A summary of
the available data is given in Table 1.
Phenacetin. Barraclough and Nilan [43] reported
that the tubular transport of phenacetin was influ-
enced by vasopressin and that under conditions of
antidiuresis there was an increased concentration of
phenacetin in the medulla, relative to the cortex.
Their method [44] of determining phenacetin, how-
ever, has been shown to be unsuitable for urinary
and kidney tissue samples, as the method simulta-
neously determines both phenacetin and a metabo-
lite [45]. In a study [45] using a specific high-per-
formance liquid chromatography method for deter-
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Phenacetin (dog) 1 1 1 1 +
Paracetamol (dog) 1 1.5 4 16 +
Paracetamol conjugates (dog) 1 1 5 95 0
Salicylate (rabbit) 1 6 13 90 +
Inulin (dog) 1 1.5 8 100 0
Data is from literature for antidiuresis [32, 35, 511 (Caterson and Duggin, unpublished). Plasma concentrations were normalized to
unity; for purposes of summary, a single value was obtained by inspection of available graphs.
mining phenacetin [46], it was demonstrated that
both under conditions of diuresis and antidiuresis,
no corticopapillary concentration gradient devel-
oped. Further analysis of these data has indicated
that phenacetin is distributed uniformly in the intra-
tubular, intracellular, and interstitial compartments
of both the cortex and medulla (Table 1).
Paracetamol. There are only two studies on the
renal distribution of paracetamol. Bluemle and
Goldberg [47], in a study in dogs, examined the re-
nal cortical, corticomedullary junction, and medul-
lary concentrations of paracetamol, following the
administration of phenacetin. Their data indicated
that during antidiuresis there was a significant corti-
copapillary concentration gradient, and that during
diuresis, no gradient developed. The gradient was
similar to that developed for the polar conjugates of
paracetamol. They concluded that paracetamol and
its conjugates were transported in a manner similar
to urea and underwent countercurrent multiplica-
tion. The possibility was not considered, however,
that the compounds might exist at different concen-
trations in different compartments within the me-
dulla. In the distal nephron within the renal me-
dulla, one would expect the highly polar conjugates
of paracetamol to be confined to the tubular lumen.
The concentration would be high within this com-
partment because of the proximal tubular secretion
of these conjugates and the reabsorption of water
along the length of the tubule. The moderately polar
parent drug, paracetamol, might be expected to dif-
fuse into the cells and interstitial fluid. Duggin and
Mudge [48] tested this hypothesis in a study in dogs,
using inulin as a marker because it is an inert non-
reabsorbable compound. Concentrations in the
urine were used for reference in the calculation of
the volume of distribution within the medulla. The
volume of distribution for the conjugates of para-
cetamol in the medulla was similar to that of inulin,
but the volume of distribution of paracetamol in the
medulla was on the average 2.3 times larger than
that of inulin during both antidiuresis and diuresis.
Thus, because inulin is confined to the intratubular
and interstitial compartments, paracetamol must be
distributed within the cells of the medulla. The med-
ullary concentration reached as high as seven times
the cortical concentration during antidiuresis, but
this gradient was absent in diuresis.
Aspirin. There have been no published studies on
the intrarenal distribution of aspirin. Caterson and
Duggin (unpublished) have studied this in rabbits.
The mean renal cortical concentration was one half
that of the plasma. During diuresis there was a small
corticopapillary concentration gradient, 1.0:1.2,
which increased to 1.0:4.5 during antidiuresis (U/P
inulin, between 60 and 160). The volume of distribu-
tion in the medulla was greater than that of inulin,
indicating an intracellular distribution, and this vol-
ume was increased in animals with an acid urine. In
the rabbit, urine pH did not fall below 6.7; a far
lower minimal pH would be anticipated in man. It is
possible, therefore, that with maximal acidification
the volume of distribution of aspirin within the pa-
pilla would be greater in man than in the rabbit.
Salicylate. Despite the large number of studies on
the renal excretion and renal tubular transport of
salicylate, there have been but few studies on its
renal concentration and intrarenal distribution.
Quintanilla and Kessler [49] studied the renal clear-
ance in dogs and also performed a limited number of
investigations on the renal cortical and medullary
concentrations. They found a concentration in the
cortex of 0.5 times the plasma, and the medullary
concentration to be the same as the plasma concen-
tration, making a corticopapillary concentration
gradient of 1:2. Bluemle and Goldberg [47] studied
the renal cortical, corticomedullary junction, and
medullary concentration of salicylate during diure-
sis and antidiuresis. Their data may be questioned,
however, because of the analytic method used [50].
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This is suitable for determining the salicylate con-
centration in plasma, but unsuitable for determining
urine or tissue concentrations, because of the pres-
ence of interfering metabolites. Caterson and Dug-
gin [51] studied rabbits following the i.v. adminis-
tration of salicylate or aspirin. Using a specific high-
performance liquid chromatography method for de-
termining salicylate [39], they showed that during
diuresis the mean salicylate concentration in the
cortex was 1.8 times that of the plasma; in the renal
medulla, the concentration was 3.4 times the
plasma. The resultant corticomedullary gradient
was 1.0:1.9. During antidiuresis, the mean concen-
tration in the cortex was 6 times that in the plasma,
and in the medulla was 13.2 times, giving a corti-
comedullary concentration ratio of 1.0:2.2. They al-
so compared the intrarenal distribution of salicylate
with that of inulin. Salicylate was distributed with-
in the tubules and the cells of the medulla. The vol-
ume of distribution increased with an acid urine and
was decreased with an alkaline urine. As with aspi-
rin, this pH dependence might be expected to be
particularly important in man in whom the urine is
normally acid, particularly during antidiuresis.
Beyer and Gelanden [52] studied the concentration
of salicylate in the dog and found a corticopapillary
concentration ratio of 1.5 to 2.0 during diuresis and
2.0 to 3.0 during antidiuresis. Although they did not
study the intrarenal distribution further, their data
would support that of Caterson and Duggin [51].
Metabolism of analgesics within the kidney
The activation by metabolism of a variety of
xenobiotics to toxic chemicals has been well de-
scribed in the liver [53]. There are only a limited
number of studies on metabolic activation of drugs
within the kidney (for review see Anders, this issue
[541).
It has been observed that patients consuming
massive doses of paracetamol (as an overdosage
with suicidal intent) will have, as a result, acute he-
patic necrosis [55]. The mechanisms for this have
been studied by Jollow et al [56] and Mitchell et al
[57], who have demonstrated that paracetamol un-
dergoes metabolic activation to a chemically reac-
tive intermediate, which conjugates with the tripep-
tide glutathione. In the massive overdosage situa-
tion, however, the cellular glutathione becomes
depleted by conjugation to paracetamol, leaving the
cell unprotected against electrophilic attack, and
the reactive intermediate then covalently combines
with cellular proteins. The end result of this series
of reactions is cellular necrosis. The reactive inter-
mediate was originally postulated to be N-OH para-
cetamol [56], but recent evidence by this group
casts some doubt on this hypothesis [58].
There are now numerous reports of acute renal
failure in patients following paracetamol over-
dosage [59]. Mudge, Gemborys, and Duggin [60]
and McMurtry, Snodgrass, and Mitchell [61] have
demonstrated that a similar mechanism of metabol-
ic activation and glutathione depletion exists within
the kidney. The mechanism of acute renal failure
following paracetamol overdosage does not, how-
ever, mimic the disease state of analgesic nephropa-
thy, where the principal lesion occurs in the renal
papilla and medulla, and not in the renal cortex, and
there has not, to date, been reported hepatic dam-
age in patients with analgesic nephropathy. Thus,
the mechanism for analgesic nephropathy must be
somewhat different than that of the acute over-
dosage situation. Paracetamol, aspirin, and saucy-
late during antidiuresis achieve higher concentra-
tions in the renal medulla than they do in the renal
cortex or other tissues. The concentration of para-
cetamol in the medulla may be five to seven times
higher than is that in the renal cortex. In this situa-
tion, the concentration of the drug in the medulla
after a large therapeutic dose will be equivalent to
the concentration in the liver following an over-
dosage of the drug.
Paracetamol undergoes metabolic activation to a
reactive intermediate in the renal cortex [60, 61] and
the renal medulla [62]. In the renal cortex, this ap-
pears to be mediated by a microsomal cytochrome
P450-dependent monoxygenase (as in the liver). In
the papilla, there is only a minimal concentration of
cytochrome P450 (Duggin and Mohandas, unpub-
lished). Electron microscopy indicates that there
are only small numbers of microsomes or rough
endoplasmic reticulum (Duggin and Ham, unpub-
lished). Ross et al [37] (this issue) have demon-
strated that paracetamol is metabolized in the iso-
lated perfused kidney and that metabolites derived
from glutathione conjugates are excreted.
Mohandas et al [62, 63] have compared the me-
tabolism of paracetamol in the kidney of the rabbit
to that of the C57BL/6J mouse. In the rabbit cortex
and whole kidney of C57BLI6J mouse, metabolic
activity and subsequent covalent binding are largely
dependent on NADPH, whereas in the medulla of
the rabbit, this system shows only a small degree of
activity. In the medulla of rabbits, there exists,
however, a totally different system, which leads to
covalent binding of the drug to tissue protein. This
system is independent of NADPH, is inhibited by
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fluoride (which stimulates binding in the NADPH
dependent system), and is inhibited by acetyl Co-A
and p-aminophenol. Thus, covalent binding to pro-
teins in the renal medulla is by a mechanism dif-
ferent from that which occurs in the renal cortex
and liver. Covalent binding during antidiuresis oc-
curs to a greater extent in the medulla than it does in
the cortex [60]. The half life of the paracetamol co-
valently bound to protein in the medulla is in the
order of 120 hours.
Glutathione depletion in the kidney also occurs as
a result of paracetamol administration [60, 61]. The
extent to which this occurs is not as great as that of
the liver. The kidney cells are thought, however, to
have at least two poois of glutathione [64]; one is
confined to the cell membrane, the other is intra-
cellular. It is not known whether these pools are af-
fected differently by a reactive metabolite of the
drug.
Phenacetin may not play a direct role in papillary
necrosis for two reasons. First, as a result of hepat-
ic metabolism [31], systemic, as well as urinary,
concentrations of phenacetin are extremely low.
Second, phenacetin itself does not become concen-
trated within the medulla [32]. From the hepatic me-
tabolism of phenacetin, paracetamol is formed as
the major metabolite. According to the present evi-
dence, this metabolic route accounts for the ulti-
mate nephrotoxicity that may result from the inges-
tion of phenacetin. A minor metabolite of phenace-
tin (N-hydroxy phenacetin) is a relatively stable
compound and is unlikely to act as the primary ary-
lating compound [65].
Aspirin has been demonstrated to acetylate cova-
lently serum albumin [40], hemoglobin [66], platelet
particulate protein [67], and renal cortical and med-
ullary proteins [30]. This acetylation of proteins is
via a nonenzymatic transacetylation reaction and is
presumably widespread in many tissues. The half
life of the covalently bound acetyl residues is ap-
proximately 130 hours in the renal medulla. The on-
ly functional abnormality reported as a result of this
acetylation has been the remarkable inhibition of
prostaglandin synthetase (cyclooxygenase) in the
platelet [68] and the renal cortex and medulla [30].
It is conceivable, however, that other enzyme sys-
tems may be affected, but they are unlikely to be of
major importance in the development of papillary
necrosis when aspirin is consumed alone.
Salicylate has been demonstrated to produce a
very significant reduction of renal glutathione when
administered to experimental animals, without a
change in hepatic glutathione concentration (Dug-
gin and Mudge, unpublished). The mechanism ap-
pears to be related to the high concentration of sa-
licylate achieved in the kidney, compared with the
liver [51]. The biochemical mechanism for this phe-
nomenon has not been definitely elucidated. It does
not appear to be as a result of salicylate conjugation
to the glutathione, as there have been no mercaptur-
ic acid metabolites of salicylate reported, and the
administration of labeled salicylate and labeled
glutathione does not result in the appearance of
doubly labeled conjugate (Caterson and Duggin, un-
published). Goldberg et a! [68] demonstrated that
salicylate in high concentration in vitro inhibits the
pentose phosphate shunt, which is largely respon-
sible for maintaining reduced glutathione. With in
vivo confirmation, this may ultimately prove to be
the mechanism.
Summary. Clinical and epidemiologic evidence
indicates that analgesic nephropathy results from
the excessive consumption of combination analge-
sics, especially those containing paracetamol
(acetaminophen) or its analog, phenacetin. The
most common analgesic combination currently pro-
ducing the disease in Australia contains aspirin and
paracetamol. To elucidate the mechanism of the
disease, a systematic series of studies have been un-
dertaken to examine the renal excretory mecha-
nisms, intrarenal concentration and distribution,
and renal metabolism of these drugs.
Paracetamol undergoes glomerular filtration and
is passively reabsorbed by the tubules. The drug be-
comes concentrated in the renal medulla during
antidiuresis, achieving a concentration approxi-
mately five to seven times that achieved in the renal
cortex or plasma. Phenacetin does not achieve a
concentration in the medulla greater than that in the
renal cortex or the plasma. Aspirin and salicylate
undergo proximal renal tubular secretion by the or-
ganic anion secretory system. Both are reabsorbed
by the distal nephron by nonionic diffusion and be-
come concentrated in the medulla during anti-
diuresis. In the case of aspirin, paracetamol, and sa-
licylate, all three, in addition to becoming concen-
trated in the medulla in antidiuresis, are distributed
within the intracellular compartment of that region.
Many of the biochemical events that could lead to
papillary necrosis have been defined. Salicylate de-
pletes cellular glutathione in the kidney, but the
mechanism producing this change is, as yet, un-
clear. Paracetamol becomes metabolized to a highly
reactive intermediate by both a NADPH-dependent
and a NADPH-independent mechanism, and this in-
termediate (or intermediates) subsequently cova-
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lently binds to tissue proteins when glutathione con-
centrations are reduced. In addition, aspirin direct-
ly acetylates kidney proteins but the consequences
of this reaction are not known as far as nephrotoxic-
ity is concerned. Thus, the combination of saucy-
late and paracetamol may be synergistic in increas-
ing covalent binding. This process, if repeated dai-
ly, could lead to sufficient covalent binding to
produce cell death and the disease state of analgesic
nephropathy.
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